

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 42, 47, and 51.

Listing of Claims:

1. – 41. (Cancelled)

42. (Currently Amended) An isolated recombinant human adenine nucleotide translocator (ANT) polypeptide comprising ~~an the~~ amino acid sequence of a human ANT3 polypeptide ~~that is at least 95 percent identical to a human ANT3 sequence as set forth in SEQ~~ ID NO:33, that is capable of binding an ANT ligand and that is produced by a method comprising culturing a host cell comprising a recombinant expression construct comprising at least one ~~inducible-regulated~~ promoter operably linked to a nucleic acid encoding the adenine nucleotide translocator polypeptide.

43. (Cancelled)

44. (Previously Presented) The isolated polypeptide of claim 42 wherein the human adenine nucleotide translocator polypeptide has been separated from non-recombinant ANT proteins from non-human species.

45. (Previously Presented) The isolated polypeptide of claim 42 wherein the ANT ligand competitively inhibits binding to an ANT of at least one ANT inhibitor that is selected from the group consisting of atractyloside and bongkreikic acid.

46. (Previously Presented) The isolated polypeptide of claim 42 wherein the host cell lacks an endogenous human ANT1 adenine nucleotide translocator polypeptide as set

forth in SEQ ID NO:31 and wherein the host cell lacks an endogenous human ANT2 adenine nucleotide translocator polypeptide as set forth in SEQ ID NO:32.

47. (Currently Amended) An isolated recombinant human adenine nucleotide translocator (ANT) fusion protein comprising an ~~adenine nucleotide translocator~~ (ANT) polypeptide fused to at least one additional polypeptide sequence, wherein the ANT polypeptide comprises ~~an~~ the amino acid sequence of a human ANT3 polypeptide that is at least 95 percent identical to a human ANT3 sequence as set forth in SEQ ID NO:33.

48. (Original) The fusion protein of claim 47 wherein said one additional polypeptide sequence is an enzyme sequence or a variant or fragment thereof.

49. (Original) The fusion protein of claim 47 wherein said fusion protein localizes to membranes.

50. (Original) The fusion protein of claim 49 wherein said membranes are mitochondrial membranes.

51. (Currently Amended) An isolated human adenine nucleotide translocator (ANT) fusion protein comprising an ~~adenine translocator~~ ANT polypeptide fused to at least one additional polypeptide sequence cleavable by a protease that separates the ~~adenine translocator~~ ANT polypeptide from the remainder of the fusion protein, said ~~adenine nucleotide translocator~~ ANT polypeptide being capable of binding an ANT ligand, wherein the ANT polypeptide comprises ~~an~~ the amino acid sequence of a human ANT3 polypeptide that is at least 95 percent identical to a human ANT3 sequence as set forth in SEQ ID NO:33.

52. (Previously Presented) An isolated human recombinant adenine nucleotide translocator according to claim 42 wherein the host cell is selected from the group consisting of a lower eukaryotic cell and a prokaryotic cell.

53. – 55. (Cancelled)

56. (Previously Presented) An isolated recombinant human adenine nucleotide translocator polypeptide according to claim 42 that is present in an intact mitochondrion or in a submitochondrial particle.

57. (Previously Presented) The fusion protein of claim 47 wherein the additional polypeptide sequence is a polypeptide having affinity for a ligand.

58. – 101. (Cancelled)